249 related articles for article (PubMed ID: 10952476)
1. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
2. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain.
Babul N; Provencher L; Laberge F; Harsanyi Z; Moulin D
J Clin Pharmacol; 1998 Jan; 38(1):74-81. PubMed ID: 9597563
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
Thirlwell MP; Sloan PA; Maroun JA; Boos GJ; Besner JG; Stewart JH; Mount BM
Cancer; 1989 Jun; 63(11 Suppl):2275-83. PubMed ID: 2720576
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.
Poulain P; Hoskin PJ; Hanks GW; A-Omar O; Walker VA; Johnston A; Turner P; Aherne GW
Br J Anaesth; 1988 Nov; 61(5):569-74. PubMed ID: 3207527
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled trial of the activity of the morphine glucuronides.
Penson RT; Joel SP; Bakhshi K; Clark SJ; Langford RM; Slevin ML
Clin Pharmacol Ther; 2000 Dec; 68(6):667-76. PubMed ID: 11180027
[TBL] [Abstract][Full Text] [Related]
11. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
Gourlay GK
Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
[TBL] [Abstract][Full Text] [Related]
12. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Kinzler ER; Pantaleon C; Aigner S
Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
14. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
[TBL] [Abstract][Full Text] [Related]
16. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine?
Christrup LL; Sjøgren P; Jensen NH; Banning AM; Elbaek K; Ersbøll AK
J Pain Symptom Manage; 1999 Sep; 18(3):164-73. PubMed ID: 10517037
[TBL] [Abstract][Full Text] [Related]
17. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.
Wilkinson TJ; Robinson BA; Begg EJ; Duffull SB; Ravenscroft PJ; Schneider JJ
Cancer Chemother Pharmacol; 1992; 31(3):251-4. PubMed ID: 1464164
[TBL] [Abstract][Full Text] [Related]
19. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.
Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML
Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain.
Bruera E; Fainsinger R; Spachynski K; Babul N; Harsanyi Z; Darke AC
J Clin Pharmacol; 1995 Jul; 35(7):666-72. PubMed ID: 7560246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
